Smaller doses of COVID-19 booster vaccines can provide long-lasting immunity, helping to reduce costs and improve access to ...

Smaller doses of COVID-19 booster vaccines can provide long-lasting immunity, helping reduce costs and improve access to ...

VRBPAC endorsed mRNA-1010 for adults 50-64 and ≥65 years, unanimously concluding benefits outweighed risks, supporting a late-stage regulatory path toward potential first mRNA seasonal influenza ...

Buy Moderna (MRNA). The FDA advisory panel unanimously supported mRNA-1010/mFLUSIVA for adults 50–64 and 65+, and the stock is already reacting to pipeline progress plus encouraging flu-shot data.

The study also reviews the great potential of mRNA vaccines to treat influenza, RSV, cancer, and autoimmune diseases.

The review draws the formal regulatory distinction: gene therapy involves the deliberate and permanent alteration of a patient's genome. mRNA vaccines do not ...

On June 18, Moderna disclosed how a Food and Drug Administration (FDA) advisory committee voted unanimously that the benefits of its mRNA-based flu vaccine, mRNA-1010, outweigh the risks among ...

Jason is a general assignment reporter, with particular focus on genetic medicine and rare disease. Confidential tips can be sent on Signal at JasonMast.77. Among all the awards and mementos Moderna ...

Moderna shares were up 13% Friday after the biotech company revealed a new effort to make a treatment for autoimmune disorders and outlined several experimental drug projects that could help it ...

Moderna (MRNA) shares surged nearly ~15% on Friday to around ~$69 and are now up almost ~42% over the past month. The Moderna stock rally came after the company shared a major business update on its ...

MRNA surged 14%, dwarfing the 2% gains of MRK and PFE, driven by an FDA flu vaccine endorsement and a blowout Q1 revenue beat. Despite MRNA's 130% YTD surge, Wall Street's consensus target of $43 sits ...